CLINICAL PHARMACOKINETICS - NIH Clinical...
Transcript of CLINICAL PHARMACOKINETICS - NIH Clinical...
![Page 1: CLINICAL PHARMACOKINETICS - NIH Clinical Centercc.nih.gov/.../slides/Clinical_Pharmacokinetics_2008_2009.pdf · CLINICAL PHARMACOKINETICS Juan J.L. Lertora, M.D., Ph.D. ... RADIOIMMUNOASSAY](https://reader031.fdocuments.us/reader031/viewer/2022021622/5b8949707f8b9abe1e8d4b4d/html5/thumbnails/1.jpg)
CLINICAL PHARMACOKINETICS Juan J.L. Lertora, M.D., Ph.D.
Director Clinical Pharmacology Program
Office of Clinical Research Training and Medical Education
National Institutes of Health Clinical Center
![Page 2: CLINICAL PHARMACOKINETICS - NIH Clinical Centercc.nih.gov/.../slides/Clinical_Pharmacokinetics_2008_2009.pdf · CLINICAL PHARMACOKINETICS Juan J.L. Lertora, M.D., Ph.D. ... RADIOIMMUNOASSAY](https://reader031.fdocuments.us/reader031/viewer/2022021622/5b8949707f8b9abe1e8d4b4d/html5/thumbnails/2.jpg)
USES OF PHARMACOKINETICS • Basis for rational dose selection in therapeutics • Development and evaluation of new drugs • Basic studies of drug distribution (PET Scan)
![Page 3: CLINICAL PHARMACOKINETICS - NIH Clinical Centercc.nih.gov/.../slides/Clinical_Pharmacokinetics_2008_2009.pdf · CLINICAL PHARMACOKINETICS Juan J.L. Lertora, M.D., Ph.D. ... RADIOIMMUNOASSAY](https://reader031.fdocuments.us/reader031/viewer/2022021622/5b8949707f8b9abe1e8d4b4d/html5/thumbnails/3.jpg)
Target Concentration Strategy ESTIMATE INITIAL DOSE TARGET LEVEL LOADING DOSE MAINTENANCE DOSE Down arrow Begin therapy Down arrow Assess Therapy Patient Response Drug level Down arrow Refine Dose Estimate – Arrow back to Assess Therapy Adjust Dose (return to Assess Therapy)
![Page 4: CLINICAL PHARMACOKINETICS - NIH Clinical Centercc.nih.gov/.../slides/Clinical_Pharmacokinetics_2008_2009.pdf · CLINICAL PHARMACOKINETICS Juan J.L. Lertora, M.D., Ph.D. ... RADIOIMMUNOASSAY](https://reader031.fdocuments.us/reader031/viewer/2022021622/5b8949707f8b9abe1e8d4b4d/html5/thumbnails/4.jpg)
RATIONALE FOR
PLASMA LEVEL MONITORING Flowchart for rationale for plasma level monitoring beginning with Prescribed dose and ending in effect.
![Page 5: CLINICAL PHARMACOKINETICS - NIH Clinical Centercc.nih.gov/.../slides/Clinical_Pharmacokinetics_2008_2009.pdf · CLINICAL PHARMACOKINETICS Juan J.L. Lertora, M.D., Ph.D. ... RADIOIMMUNOASSAY](https://reader031.fdocuments.us/reader031/viewer/2022021622/5b8949707f8b9abe1e8d4b4d/html5/thumbnails/5.jpg)
FIRST DESCRIPTION OF THERAPEUTIC DRUG
MONITORING Copy of this article from Wuth O. JAMA 1927;88:2013-17.
![Page 6: CLINICAL PHARMACOKINETICS - NIH Clinical Centercc.nih.gov/.../slides/Clinical_Pharmacokinetics_2008_2009.pdf · CLINICAL PHARMACOKINETICS Juan J.L. Lertora, M.D., Ph.D. ... RADIOIMMUNOASSAY](https://reader031.fdocuments.us/reader031/viewer/2022021622/5b8949707f8b9abe1e8d4b4d/html5/thumbnails/6.jpg)
RADIOIMMUNOASSAY
Photo of Rosalyn Sussman Yalow – 1977 Nobel Laureate
![Page 7: CLINICAL PHARMACOKINETICS - NIH Clinical Centercc.nih.gov/.../slides/Clinical_Pharmacokinetics_2008_2009.pdf · CLINICAL PHARMACOKINETICS Juan J.L. Lertora, M.D., Ph.D. ... RADIOIMMUNOASSAY](https://reader031.fdocuments.us/reader031/viewer/2022021622/5b8949707f8b9abe1e8d4b4d/html5/thumbnails/7.jpg)
GAS LIQUID CHROMATOGRAPHY Photo of gas liquid chromatography
![Page 8: CLINICAL PHARMACOKINETICS - NIH Clinical Centercc.nih.gov/.../slides/Clinical_Pharmacokinetics_2008_2009.pdf · CLINICAL PHARMACOKINETICS Juan J.L. Lertora, M.D., Ph.D. ... RADIOIMMUNOASSAY](https://reader031.fdocuments.us/reader031/viewer/2022021622/5b8949707f8b9abe1e8d4b4d/html5/thumbnails/8.jpg)
HIGH PERFORMANCE
LIQUID CHROMATOGRAPHY Photo of high performance liquid chromatograph
![Page 9: CLINICAL PHARMACOKINETICS - NIH Clinical Centercc.nih.gov/.../slides/Clinical_Pharmacokinetics_2008_2009.pdf · CLINICAL PHARMACOKINETICS Juan J.L. Lertora, M.D., Ph.D. ... RADIOIMMUNOASSAY](https://reader031.fdocuments.us/reader031/viewer/2022021622/5b8949707f8b9abe1e8d4b4d/html5/thumbnails/9.jpg)
FLUORESCENCE POLARIZATION IMMUNOASSAY
Photo of TDX FPIA Analyzer
![Page 10: CLINICAL PHARMACOKINETICS - NIH Clinical Centercc.nih.gov/.../slides/Clinical_Pharmacokinetics_2008_2009.pdf · CLINICAL PHARMACOKINETICS Juan J.L. Lertora, M.D., Ph.D. ... RADIOIMMUNOASSAY](https://reader031.fdocuments.us/reader031/viewer/2022021622/5b8949707f8b9abe1e8d4b4d/html5/thumbnails/10.jpg)
DRUG CANDIDATES FOR TDM • Low therapeutic index • No physiologic or therapeutic endpoints to guide dosage • Pharmacokinetics vary widely between individuals • Need to monitor adherence?
![Page 11: CLINICAL PHARMACOKINETICS - NIH Clinical Centercc.nih.gov/.../slides/Clinical_Pharmacokinetics_2008_2009.pdf · CLINICAL PHARMACOKINETICS Juan J.L. Lertora, M.D., Ph.D. ... RADIOIMMUNOASSAY](https://reader031.fdocuments.us/reader031/viewer/2022021622/5b8949707f8b9abe1e8d4b4d/html5/thumbnails/11.jpg)
EFFECT OF ADHERENCE RATE ON
OUTCOME IN HIV INFECTED PATIENTS Bar chart showing virologic failure rates and percent of adherence rates. Adherence improves treatment outcome.
![Page 12: CLINICAL PHARMACOKINETICS - NIH Clinical Centercc.nih.gov/.../slides/Clinical_Pharmacokinetics_2008_2009.pdf · CLINICAL PHARMACOKINETICS Juan J.L. Lertora, M.D., Ph.D. ... RADIOIMMUNOASSAY](https://reader031.fdocuments.us/reader031/viewer/2022021622/5b8949707f8b9abe1e8d4b4d/html5/thumbnails/12.jpg)
INDICATIONS for Measuring Blood Levels • To evaluate suspected toxicity • To evaluate actual or potential lack of therapeutic
efficacy • To monitor prophylactic therapy • To guide dose adjustment
![Page 13: CLINICAL PHARMACOKINETICS - NIH Clinical Centercc.nih.gov/.../slides/Clinical_Pharmacokinetics_2008_2009.pdf · CLINICAL PHARMACOKINETICS Juan J.L. Lertora, M.D., Ph.D. ... RADIOIMMUNOASSAY](https://reader031.fdocuments.us/reader031/viewer/2022021622/5b8949707f8b9abe1e8d4b4d/html5/thumbnails/13.jpg)
Target Concentration Strategy Estimate initial dose Target level Loading dose Maintenance dose
![Page 14: CLINICAL PHARMACOKINETICS - NIH Clinical Centercc.nih.gov/.../slides/Clinical_Pharmacokinetics_2008_2009.pdf · CLINICAL PHARMACOKINETICS Juan J.L. Lertora, M.D., Ph.D. ... RADIOIMMUNOASSAY](https://reader031.fdocuments.us/reader031/viewer/2022021622/5b8949707f8b9abe1e8d4b4d/html5/thumbnails/14.jpg)
DIGOXIN Levels in TOXIC and NONTOXIC Patients*
Chart showing that from Smith TW and Haber E. J Clin Invest 1970;49-2377-86
![Page 15: CLINICAL PHARMACOKINETICS - NIH Clinical Centercc.nih.gov/.../slides/Clinical_Pharmacokinetics_2008_2009.pdf · CLINICAL PHARMACOKINETICS Juan J.L. Lertora, M.D., Ph.D. ... RADIOIMMUNOASSAY](https://reader031.fdocuments.us/reader031/viewer/2022021622/5b8949707f8b9abe1e8d4b4d/html5/thumbnails/15.jpg)
DIGOXIN: Factors Influencing OUTCOME in “GREY ZONE”
Up Arrow - Risk of toxicity in patients with coronary heart disease, hypoxemia, and/or hypokalemia, hypomagnesemia Down Arrow - ECG evidence of toxicity if concurrent therapy with antiarrhythmic drugs
![Page 16: CLINICAL PHARMACOKINETICS - NIH Clinical Centercc.nih.gov/.../slides/Clinical_Pharmacokinetics_2008_2009.pdf · CLINICAL PHARMACOKINETICS Juan J.L. Lertora, M.D., Ph.D. ... RADIOIMMUNOASSAY](https://reader031.fdocuments.us/reader031/viewer/2022021622/5b8949707f8b9abe1e8d4b4d/html5/thumbnails/16.jpg)
TRADITIONAL Guidelines
for DIGOXIN Levels THERAPEUTIC RANGE: 0.8 - 1.6 ng/mL POSSIBLY TOXIC LEVELS: 1.6 - 3.0 ng/mL PROBABLY TOXIC LEVELS: greater than 3.0 ng/mL
![Page 17: CLINICAL PHARMACOKINETICS - NIH Clinical Centercc.nih.gov/.../slides/Clinical_Pharmacokinetics_2008_2009.pdf · CLINICAL PHARMACOKINETICS Juan J.L. Lertora, M.D., Ph.D. ... RADIOIMMUNOASSAY](https://reader031.fdocuments.us/reader031/viewer/2022021622/5b8949707f8b9abe1e8d4b4d/html5/thumbnails/17.jpg)
SURVIVAL as a function of DIGOXIN LEVEL measured after 1 Month Rx* Chart illustrating that from Rathore SS, et Al. JAMA 2003;289:871-8
![Page 18: CLINICAL PHARMACOKINETICS - NIH Clinical Centercc.nih.gov/.../slides/Clinical_Pharmacokinetics_2008_2009.pdf · CLINICAL PHARMACOKINETICS Juan J.L. Lertora, M.D., Ph.D. ... RADIOIMMUNOASSAY](https://reader031.fdocuments.us/reader031/viewer/2022021622/5b8949707f8b9abe1e8d4b4d/html5/thumbnails/18.jpg)
PROPOSED Range of DIGOXIN LEVELS for OPTIMAL
THERAPY in CHF New Therapeutic Range: 0.5 - 0.9 ng/mL Benefit results from INHIBITION OF SYMPATHETIC NERVOUS SYSTEM rather than (up arrow) INOTROPY BUT DIGOXIN DOSES PRESCRIBED FOR PATIENTS WITH THIS RANGE OF DIGOXIN LEVELS SHOULD HAVE BEEN ASSOCIATED WITH HIGHER LEVELS?
![Page 19: CLINICAL PHARMACOKINETICS - NIH Clinical Centercc.nih.gov/.../slides/Clinical_Pharmacokinetics_2008_2009.pdf · CLINICAL PHARMACOKINETICS Juan J.L. Lertora, M.D., Ph.D. ... RADIOIMMUNOASSAY](https://reader031.fdocuments.us/reader031/viewer/2022021622/5b8949707f8b9abe1e8d4b4d/html5/thumbnails/19.jpg)
DIGOXIN DOSES for Patients with Levels of 0.5 - 0.8 ng/mL
Bar chart showing percent of patients taking four different daily doses of Digoxin from Rathore SS, et al. JAMA 2003,289:871-8
![Page 20: CLINICAL PHARMACOKINETICS - NIH Clinical Centercc.nih.gov/.../slides/Clinical_Pharmacokinetics_2008_2009.pdf · CLINICAL PHARMACOKINETICS Juan J.L. Lertora, M.D., Ph.D. ... RADIOIMMUNOASSAY](https://reader031.fdocuments.us/reader031/viewer/2022021622/5b8949707f8b9abe1e8d4b4d/html5/thumbnails/20.jpg)
Target Concentration Strategy ESTIMATE INITIAL DOSE TARGET LEVEL LOADING DOSE MAINTENANCE DOSE BASED ON CONCEPT OF DISTRIBUTION VOLUME
![Page 21: CLINICAL PHARMACOKINETICS - NIH Clinical Centercc.nih.gov/.../slides/Clinical_Pharmacokinetics_2008_2009.pdf · CLINICAL PHARMACOKINETICS Juan J.L. Lertora, M.D., Ph.D. ... RADIOIMMUNOASSAY](https://reader031.fdocuments.us/reader031/viewer/2022021622/5b8949707f8b9abe1e8d4b4d/html5/thumbnails/21.jpg)
DIGOXIN LEVELS after IV Dose Chart illustrating this showing the distribution phase and the elimination phase
![Page 22: CLINICAL PHARMACOKINETICS - NIH Clinical Centercc.nih.gov/.../slides/Clinical_Pharmacokinetics_2008_2009.pdf · CLINICAL PHARMACOKINETICS Juan J.L. Lertora, M.D., Ph.D. ... RADIOIMMUNOASSAY](https://reader031.fdocuments.us/reader031/viewer/2022021622/5b8949707f8b9abe1e8d4b4d/html5/thumbnails/22.jpg)
Initial Digitalization Formula relating initial dose, initial digoxin concentration and apparent volume of distribution.
![Page 23: CLINICAL PHARMACOKINETICS - NIH Clinical Centercc.nih.gov/.../slides/Clinical_Pharmacokinetics_2008_2009.pdf · CLINICAL PHARMACOKINETICS Juan J.L. Lertora, M.D., Ph.D. ... RADIOIMMUNOASSAY](https://reader031.fdocuments.us/reader031/viewer/2022021622/5b8949707f8b9abe1e8d4b4d/html5/thumbnails/23.jpg)
3 DISTRIBUTION VOLUMES
![Page 24: CLINICAL PHARMACOKINETICS - NIH Clinical Centercc.nih.gov/.../slides/Clinical_Pharmacokinetics_2008_2009.pdf · CLINICAL PHARMACOKINETICS Juan J.L. Lertora, M.D., Ph.D. ... RADIOIMMUNOASSAY](https://reader031.fdocuments.us/reader031/viewer/2022021622/5b8949707f8b9abe1e8d4b4d/html5/thumbnails/24.jpg)
DISTRIBUTION DELAYS ONSET
of DIGOXIN Chronotropic Action* Chart from Gold H, et al. J Pharmacol Exp Ther 1953;109:45-57
![Page 25: CLINICAL PHARMACOKINETICS - NIH Clinical Centercc.nih.gov/.../slides/Clinical_Pharmacokinetics_2008_2009.pdf · CLINICAL PHARMACOKINETICS Juan J.L. Lertora, M.D., Ph.D. ... RADIOIMMUNOASSAY](https://reader031.fdocuments.us/reader031/viewer/2022021622/5b8949707f8b9abe1e8d4b4d/html5/thumbnails/25.jpg)
DISTRIBUTION DELAYS ONSET of
DIGOXIN Inotropic Action* Chart
![Page 26: CLINICAL PHARMACOKINETICS - NIH Clinical Centercc.nih.gov/.../slides/Clinical_Pharmacokinetics_2008_2009.pdf · CLINICAL PHARMACOKINETICS Juan J.L. Lertora, M.D., Ph.D. ... RADIOIMMUNOASSAY](https://reader031.fdocuments.us/reader031/viewer/2022021622/5b8949707f8b9abe1e8d4b4d/html5/thumbnails/26.jpg)
Target Concentration Strategy Estimate initial dose Target level Loading dose Maintenance dose Based on concepts Elimination half life and clearance
![Page 27: CLINICAL PHARMACOKINETICS - NIH Clinical Centercc.nih.gov/.../slides/Clinical_Pharmacokinetics_2008_2009.pdf · CLINICAL PHARMACOKINETICS Juan J.L. Lertora, M.D., Ph.D. ... RADIOIMMUNOASSAY](https://reader031.fdocuments.us/reader031/viewer/2022021622/5b8949707f8b9abe1e8d4b4d/html5/thumbnails/27.jpg)
ELIMINATION HALF-LIFE ELIMINATION HALF-LIFE IS THE TIME REQUIRED FOR THE PLASMA CONCENTRATION (OR TOTAL BODY STORES) OF A DRUG TO FALL TO HALF OF THE CONCENTRATION (OR AMOUNT) PRESENT AT SOME PREVIOUS TIME.
![Page 28: CLINICAL PHARMACOKINETICS - NIH Clinical Centercc.nih.gov/.../slides/Clinical_Pharmacokinetics_2008_2009.pdf · CLINICAL PHARMACOKINETICS Juan J.L. Lertora, M.D., Ph.D. ... RADIOIMMUNOASSAY](https://reader031.fdocuments.us/reader031/viewer/2022021622/5b8949707f8b9abe1e8d4b4d/html5/thumbnails/28.jpg)
ELIMINATION PARAMETERS t ½ = elimination half life k = elimination rate CLE = elimination clearance
![Page 29: CLINICAL PHARMACOKINETICS - NIH Clinical Centercc.nih.gov/.../slides/Clinical_Pharmacokinetics_2008_2009.pdf · CLINICAL PHARMACOKINETICS Juan J.L. Lertora, M.D., Ph.D. ... RADIOIMMUNOASSAY](https://reader031.fdocuments.us/reader031/viewer/2022021622/5b8949707f8b9abe1e8d4b4d/html5/thumbnails/29.jpg)
Maintenance Digoxin Therapy Formula relating maintenance dose to daily digoxin loss from the body.
![Page 30: CLINICAL PHARMACOKINETICS - NIH Clinical Centercc.nih.gov/.../slides/Clinical_Pharmacokinetics_2008_2009.pdf · CLINICAL PHARMACOKINETICS Juan J.L. Lertora, M.D., Ph.D. ... RADIOIMMUNOASSAY](https://reader031.fdocuments.us/reader031/viewer/2022021622/5b8949707f8b9abe1e8d4b4d/html5/thumbnails/30.jpg)
DIGOXIN CUMULATION Formula showing exponential accumulation of digoxin.
![Page 31: CLINICAL PHARMACOKINETICS - NIH Clinical Centercc.nih.gov/.../slides/Clinical_Pharmacokinetics_2008_2009.pdf · CLINICAL PHARMACOKINETICS Juan J.L. Lertora, M.D., Ph.D. ... RADIOIMMUNOASSAY](https://reader031.fdocuments.us/reader031/viewer/2022021622/5b8949707f8b9abe1e8d4b4d/html5/thumbnails/31.jpg)
CUMULATION FACTOR τ = dose interval k = elimination rate constant
τ = dose interval k = elimination rate constant
![Page 32: CLINICAL PHARMACOKINETICS - NIH Clinical Centercc.nih.gov/.../slides/Clinical_Pharmacokinetics_2008_2009.pdf · CLINICAL PHARMACOKINETICS Juan J.L. Lertora, M.D., Ph.D. ... RADIOIMMUNOASSAY](https://reader031.fdocuments.us/reader031/viewer/2022021622/5b8949707f8b9abe1e8d4b4d/html5/thumbnails/32.jpg)
ELIMINATION RATE CONSTANT
![Page 33: CLINICAL PHARMACOKINETICS - NIH Clinical Centercc.nih.gov/.../slides/Clinical_Pharmacokinetics_2008_2009.pdf · CLINICAL PHARMACOKINETICS Juan J.L. Lertora, M.D., Ph.D. ... RADIOIMMUNOASSAY](https://reader031.fdocuments.us/reader031/viewer/2022021622/5b8949707f8b9abe1e8d4b4d/html5/thumbnails/33.jpg)
LOADING & MAINTENANCE DOSES Chart showing Digoxin levels over time as a function of loading and maintenance dosing.
![Page 34: CLINICAL PHARMACOKINETICS - NIH Clinical Centercc.nih.gov/.../slides/Clinical_Pharmacokinetics_2008_2009.pdf · CLINICAL PHARMACOKINETICS Juan J.L. Lertora, M.D., Ph.D. ... RADIOIMMUNOASSAY](https://reader031.fdocuments.us/reader031/viewer/2022021622/5b8949707f8b9abe1e8d4b4d/html5/thumbnails/34.jpg)
TIME-COURSE OF DIGOXIN CUMULATION Chart showing plasma Digoxin levels over time. Steady-state levels take longer to be reached in patients with uremia.
![Page 35: CLINICAL PHARMACOKINETICS - NIH Clinical Centercc.nih.gov/.../slides/Clinical_Pharmacokinetics_2008_2009.pdf · CLINICAL PHARMACOKINETICS Juan J.L. Lertora, M.D., Ph.D. ... RADIOIMMUNOASSAY](https://reader031.fdocuments.us/reader031/viewer/2022021622/5b8949707f8b9abe1e8d4b4d/html5/thumbnails/35.jpg)
DIGOXIN CASE HISTORY A 39 year-old man with mitral stenosis was hospitalized for mitral valve replacement (October 1981). He had a history of chronic renal failure resulting from interstitial nephritis and was maintained on hemodialysis. His mitral valve was replaced with a prosthesis and digoxin therapy was initiated postoperatively in a dose 0.25 mg/day.
![Page 36: CLINICAL PHARMACOKINETICS - NIH Clinical Centercc.nih.gov/.../slides/Clinical_Pharmacokinetics_2008_2009.pdf · CLINICAL PHARMACOKINETICS Juan J.L. Lertora, M.D., Ph.D. ... RADIOIMMUNOASSAY](https://reader031.fdocuments.us/reader031/viewer/2022021622/5b8949707f8b9abe1e8d4b4d/html5/thumbnails/36.jpg)
DIGOXIN CASE HISTORY (cont.) Two weeks later, he was noted to be unusually restless in the evening. The following day, he died shortly after he received his morning Digoxin dose. Blood was obtained during an unsuccessful resuscitation attempt, and the measured plasma Digoxin concentration was 6.9 ng/mL.
![Page 37: CLINICAL PHARMACOKINETICS - NIH Clinical Centercc.nih.gov/.../slides/Clinical_Pharmacokinetics_2008_2009.pdf · CLINICAL PHARMACOKINETICS Juan J.L. Lertora, M.D., Ph.D. ... RADIOIMMUNOASSAY](https://reader031.fdocuments.us/reader031/viewer/2022021622/5b8949707f8b9abe1e8d4b4d/html5/thumbnails/37.jpg)
Target Concentration Strategy ESTIMATE INITIAL DOSE TARGET LEVEL LOADING DOSE MAINTENANCE DOSE Down arrow BEGIN THERAPY Down arrow ASSESS THERAPY PATIENT RESPONSE DRUG LEVEL Down Arrow REFINE DOSE ESTIMATE Down arrow ADJUST DOSE (Arrow back to Assess Therapy)
![Page 38: CLINICAL PHARMACOKINETICS - NIH Clinical Centercc.nih.gov/.../slides/Clinical_Pharmacokinetics_2008_2009.pdf · CLINICAL PHARMACOKINETICS Juan J.L. Lertora, M.D., Ph.D. ... RADIOIMMUNOASSAY](https://reader031.fdocuments.us/reader031/viewer/2022021622/5b8949707f8b9abe1e8d4b4d/html5/thumbnails/38.jpg)
Target Concentration Strategy ESTIMATE INITIAL DOSE TARGET LEVEL LOADING DOSE MAINTENANCE DOSE Down arrow BEGIN THERAPY Down arrow ASSESS THERAPY PATIENT RESPONSE DRUG LEVEL Down Arrow REFINE DOSE ESTIMATE Down arrow ADJUST DOSE (Arrow back to Assess Therapy)
![Page 39: CLINICAL PHARMACOKINETICS - NIH Clinical Centercc.nih.gov/.../slides/Clinical_Pharmacokinetics_2008_2009.pdf · CLINICAL PHARMACOKINETICS Juan J.L. Lertora, M.D., Ph.D. ... RADIOIMMUNOASSAY](https://reader031.fdocuments.us/reader031/viewer/2022021622/5b8949707f8b9abe1e8d4b4d/html5/thumbnails/39.jpg)
PHARMACOKINETIC ANALYSIS OF DIGOXIN CASE HISTORY
ESTIMATED T1/2: 4.3 days (k = 0.16 day-1) TIME TO 90% STEADY STATE: 3.3 x 4.3 = 14.2 days STEADY STATE PEAK LEVEL: 6.2 ng/mL (post distribution phase) MEASURED LEVEL: 6.9 ng/mL (pre distribution)
![Page 40: CLINICAL PHARMACOKINETICS - NIH Clinical Centercc.nih.gov/.../slides/Clinical_Pharmacokinetics_2008_2009.pdf · CLINICAL PHARMACOKINETICS Juan J.L. Lertora, M.D., Ph.D. ... RADIOIMMUNOASSAY](https://reader031.fdocuments.us/reader031/viewer/2022021622/5b8949707f8b9abe1e8d4b4d/html5/thumbnails/40.jpg)
STEADY STATE CONCENTRATION Continuous infusion: Intermittent Dosing:
![Page 41: CLINICAL PHARMACOKINETICS - NIH Clinical Centercc.nih.gov/.../slides/Clinical_Pharmacokinetics_2008_2009.pdf · CLINICAL PHARMACOKINETICS Juan J.L. Lertora, M.D., Ph.D. ... RADIOIMMUNOASSAY](https://reader031.fdocuments.us/reader031/viewer/2022021622/5b8949707f8b9abe1e8d4b4d/html5/thumbnails/41.jpg)
STEADY STATE CONCENTRATION
• Not determined by loading dose
• Mean steady state concentration not determined by Vd
• Peak and trough are affected by Vd
![Page 42: CLINICAL PHARMACOKINETICS - NIH Clinical Centercc.nih.gov/.../slides/Clinical_Pharmacokinetics_2008_2009.pdf · CLINICAL PHARMACOKINETICS Juan J.L. Lertora, M.D., Ph.D. ... RADIOIMMUNOASSAY](https://reader031.fdocuments.us/reader031/viewer/2022021622/5b8949707f8b9abe1e8d4b4d/html5/thumbnails/42.jpg)
Vd AFFECTS PEAK AND TROUGH BUT NOT MEAN LEVELS
Chart illustrating this
![Page 43: CLINICAL PHARMACOKINETICS - NIH Clinical Centercc.nih.gov/.../slides/Clinical_Pharmacokinetics_2008_2009.pdf · CLINICAL PHARMACOKINETICS Juan J.L. Lertora, M.D., Ph.D. ... RADIOIMMUNOASSAY](https://reader031.fdocuments.us/reader031/viewer/2022021622/5b8949707f8b9abe1e8d4b4d/html5/thumbnails/43.jpg)
FOR MOST DRUGS, Css IS PROPORTIONAL TO DOSE
(Dosing Rate) Continuous Infusion: Intermittent dosing:
![Page 44: CLINICAL PHARMACOKINETICS - NIH Clinical Centercc.nih.gov/.../slides/Clinical_Pharmacokinetics_2008_2009.pdf · CLINICAL PHARMACOKINETICS Juan J.L. Lertora, M.D., Ph.D. ... RADIOIMMUNOASSAY](https://reader031.fdocuments.us/reader031/viewer/2022021622/5b8949707f8b9abe1e8d4b4d/html5/thumbnails/44.jpg)
STEADY STATE CONCENTRATION
• NOT DETERMINED BY LOADING DOSE
• MEAN STEADY STATE CONCENTRATION NOT DETERMINED BY Vd
• CHANGES IN MAINTENANCE DOSE RESULT IN DIRECTLY PROPORTIONAL CHANGES IN Css FOR MOST DRUGS
![Page 45: CLINICAL PHARMACOKINETICS - NIH Clinical Centercc.nih.gov/.../slides/Clinical_Pharmacokinetics_2008_2009.pdf · CLINICAL PHARMACOKINETICS Juan J.L. Lertora, M.D., Ph.D. ... RADIOIMMUNOASSAY](https://reader031.fdocuments.us/reader031/viewer/2022021622/5b8949707f8b9abe1e8d4b4d/html5/thumbnails/45.jpg)
PHARMACOKINETIC MODELS
WHAT PHARMACOKINETIC PARAMETERS ARE PRIMARY?
![Page 46: CLINICAL PHARMACOKINETICS - NIH Clinical Centercc.nih.gov/.../slides/Clinical_Pharmacokinetics_2008_2009.pdf · CLINICAL PHARMACOKINETICS Juan J.L. Lertora, M.D., Ph.D. ... RADIOIMMUNOASSAY](https://reader031.fdocuments.us/reader031/viewer/2022021622/5b8949707f8b9abe1e8d4b4d/html5/thumbnails/46.jpg)
SINGLE COMPARTMENT MODEL
Example diagram
![Page 47: CLINICAL PHARMACOKINETICS - NIH Clinical Centercc.nih.gov/.../slides/Clinical_Pharmacokinetics_2008_2009.pdf · CLINICAL PHARMACOKINETICS Juan J.L. Lertora, M.D., Ph.D. ... RADIOIMMUNOASSAY](https://reader031.fdocuments.us/reader031/viewer/2022021622/5b8949707f8b9abe1e8d4b4d/html5/thumbnails/47.jpg)
ELIMINATION HALF-LIFE Therefore, t ½ is t a primary pharmacokinetic parameter
![Page 48: CLINICAL PHARMACOKINETICS - NIH Clinical Centercc.nih.gov/.../slides/Clinical_Pharmacokinetics_2008_2009.pdf · CLINICAL PHARMACOKINETICS Juan J.L. Lertora, M.D., Ph.D. ... RADIOIMMUNOASSAY](https://reader031.fdocuments.us/reader031/viewer/2022021622/5b8949707f8b9abe1e8d4b4d/html5/thumbnails/48.jpg)
3 DISTRIBUTION VOLUMES
![Page 49: CLINICAL PHARMACOKINETICS - NIH Clinical Centercc.nih.gov/.../slides/Clinical_Pharmacokinetics_2008_2009.pdf · CLINICAL PHARMACOKINETICS Juan J.L. Lertora, M.D., Ph.D. ... RADIOIMMUNOASSAY](https://reader031.fdocuments.us/reader031/viewer/2022021622/5b8949707f8b9abe1e8d4b4d/html5/thumbnails/49.jpg)
Some Drugs are NOT Eliminated by First Order Kinetics Phenytoin (Dilantin) Ethyl Alcohol Acetylsalicylic Acid (aspirin)
![Page 50: CLINICAL PHARMACOKINETICS - NIH Clinical Centercc.nih.gov/.../slides/Clinical_Pharmacokinetics_2008_2009.pdf · CLINICAL PHARMACOKINETICS Juan J.L. Lertora, M.D., Ph.D. ... RADIOIMMUNOASSAY](https://reader031.fdocuments.us/reader031/viewer/2022021622/5b8949707f8b9abe1e8d4b4d/html5/thumbnails/50.jpg)
Phenytoin Hydroxylation Chemical structure
![Page 51: CLINICAL PHARMACOKINETICS - NIH Clinical Centercc.nih.gov/.../slides/Clinical_Pharmacokinetics_2008_2009.pdf · CLINICAL PHARMACOKINETICS Juan J.L. Lertora, M.D., Ph.D. ... RADIOIMMUNOASSAY](https://reader031.fdocuments.us/reader031/viewer/2022021622/5b8949707f8b9abe1e8d4b4d/html5/thumbnails/51.jpg)
Chart
![Page 52: CLINICAL PHARMACOKINETICS - NIH Clinical Centercc.nih.gov/.../slides/Clinical_Pharmacokinetics_2008_2009.pdf · CLINICAL PHARMACOKINETICS Juan J.L. Lertora, M.D., Ph.D. ... RADIOIMMUNOASSAY](https://reader031.fdocuments.us/reader031/viewer/2022021622/5b8949707f8b9abe1e8d4b4d/html5/thumbnails/52.jpg)
Phenytoin Kinetics In Normal Subjects Chart depicting that.
![Page 53: CLINICAL PHARMACOKINETICS - NIH Clinical Centercc.nih.gov/.../slides/Clinical_Pharmacokinetics_2008_2009.pdf · CLINICAL PHARMACOKINETICS Juan J.L. Lertora, M.D., Ph.D. ... RADIOIMMUNOASSAY](https://reader031.fdocuments.us/reader031/viewer/2022021622/5b8949707f8b9abe1e8d4b4d/html5/thumbnails/53.jpg)
Steady State Equations
![Page 54: CLINICAL PHARMACOKINETICS - NIH Clinical Centercc.nih.gov/.../slides/Clinical_Pharmacokinetics_2008_2009.pdf · CLINICAL PHARMACOKINETICS Juan J.L. Lertora, M.D., Ph.D. ... RADIOIMMUNOASSAY](https://reader031.fdocuments.us/reader031/viewer/2022021622/5b8949707f8b9abe1e8d4b4d/html5/thumbnails/54.jpg)
Relationship of Plasma Level to Phenytoin Dose* Phenytoin Dose Plasma Level *From: Kutt H, McDowell F: J Am Med Assoc 1968:203:969-72
![Page 55: CLINICAL PHARMACOKINETICS - NIH Clinical Centercc.nih.gov/.../slides/Clinical_Pharmacokinetics_2008_2009.pdf · CLINICAL PHARMACOKINETICS Juan J.L. Lertora, M.D., Ph.D. ... RADIOIMMUNOASSAY](https://reader031.fdocuments.us/reader031/viewer/2022021622/5b8949707f8b9abe1e8d4b4d/html5/thumbnails/55.jpg)
Patient who Became Toxic on a Phenytoin Dose of 300 mg/day Chart illustrating this.
![Page 56: CLINICAL PHARMACOKINETICS - NIH Clinical Centercc.nih.gov/.../slides/Clinical_Pharmacokinetics_2008_2009.pdf · CLINICAL PHARMACOKINETICS Juan J.L. Lertora, M.D., Ph.D. ... RADIOIMMUNOASSAY](https://reader031.fdocuments.us/reader031/viewer/2022021622/5b8949707f8b9abe1e8d4b4d/html5/thumbnails/56.jpg)
Phenytoin Case History After inpatient evaluation for a generalized seizure, a 28-year-old woman was discharged on phenytoin therapy at a dose of 300 mg/day. After 5 days of therapy, she presented to the hospital’s emergency department with marked ataxia. Her phenytoin plasma concentration was found to be 27 μg/mL. She was sent home on a reduced phenytoin dose of 200 mg/day.
![Page 57: CLINICAL PHARMACOKINETICS - NIH Clinical Centercc.nih.gov/.../slides/Clinical_Pharmacokinetics_2008_2009.pdf · CLINICAL PHARMACOKINETICS Juan J.L. Lertora, M.D., Ph.D. ... RADIOIMMUNOASSAY](https://reader031.fdocuments.us/reader031/viewer/2022021622/5b8949707f8b9abe1e8d4b4d/html5/thumbnails/57.jpg)
Phenytoin Case History (cont.) Two days later, she returned to the emergency department with more severe ataxia. Her phenytoin plasma concentration was now 32 μg/mL. Non-compliance was suspected but a clinical pharmacology evaluation was requested.
![Page 58: CLINICAL PHARMACOKINETICS - NIH Clinical Centercc.nih.gov/.../slides/Clinical_Pharmacokinetics_2008_2009.pdf · CLINICAL PHARMACOKINETICS Juan J.L. Lertora, M.D., Ph.D. ... RADIOIMMUNOASSAY](https://reader031.fdocuments.us/reader031/viewer/2022021622/5b8949707f8b9abe1e8d4b4d/html5/thumbnails/58.jpg)
Patient with Very Low VMAX Chart depicting this.
![Page 59: CLINICAL PHARMACOKINETICS - NIH Clinical Centercc.nih.gov/.../slides/Clinical_Pharmacokinetics_2008_2009.pdf · CLINICAL PHARMACOKINETICS Juan J.L. Lertora, M.D., Ph.D. ... RADIOIMMUNOASSAY](https://reader031.fdocuments.us/reader031/viewer/2022021622/5b8949707f8b9abe1e8d4b4d/html5/thumbnails/59.jpg)
Concluding Thoughts
• PRACTICE PROBLEMS AT END OF CHAPTER 2 WITH ANSWERS IN APPENDIX II
• EQUATIONS DERIVED IN “PRINCIPLES OF CLINICAL PHARMACOLOGY” TEXTBOOK
• LAPLACE TRANSFORMS INTRODUCED WITH TABLES IN APPENDIX I